Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58



Cahn, Avivit, Raz, Itamar, Leiter, Lawrence A, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Bhatt, Deepak L, McGuire, Darren K
et al (show 5 more authors) (2021) Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. DIABETES CARE, 44 (5). 1159 - 1167.

[img] Text
MRF paper V3 JW.docx - Accepted Version

Download (654kB)
Item Type: Article
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 22 Mar 2021 11:44
Last Modified: 16 Jan 2022 05:10
DOI: 10.2337/dc20-2492
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3117987